Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of telisotuzumab adizutecan plus pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
CTR20264128Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab adizutecan, pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by AbbVie Inc.. Started Nov 2026; status: active.
02
Drugs
telisotuzumab adizutecanpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20264128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264128.